M Martín1, A Hinojar2, L Cerezo3, J García4, M Lopez3, J Prada2, A Marín3, C Gamallo5. 1. Department of Radiation Oncology, Instituto de Investigación Hospital de La Princesa, Diego de León 62, 28006, Madrid, Spain. margamm@yahoo.com. 2. Department of Otorhinolaryngology, Instituto de Investigación Hospital de La Princesa, Diego de León 62, 28006, Madrid, Spain. 3. Department of Radiation Oncology, Instituto de Investigación Hospital de La Princesa, Diego de León 62, 28006, Madrid, Spain. 4. Department of Otorhinolaryngology, Hospital Universitario Infanta Sofía, Paseo de Europa, 34, San Sebastián de Los Reyes, 28702, Madrid, Spain. 5. Department of Pathology, Instituto de Investigación Hospital de La Princesa, Diego de León 62, 28006, Madrid, Spain.
Abstract
BACKGROUND: Aldehyde dehydrogenase isoform 1 (ALDH1) has been shown to be a marker of cancer stem cells (CSCs). These stem cells may be responsible for tumour perpetuation as well as local and distant invasion. Several studies have shown that CSCs are more chemoradiotherapy (CRT)-resistant and may be responsible for tumour recurrence. Other studies, in contrast, have found ALDH1 expression to be indicative of a better prognosis. METHODS: We retrospectively evaluated 84 patients diagnosed and treated for laryngeal cancer between 2006 and 2011. All patients underwent curative-intent radiotherapy or CRT at our institution. 57 of the 84 tumour samples contained sufficient material for ALDH1 assessment. RESULTS: ALDH1 expression was detected in 17.5 % (10/57) of the tissue samples. None of the tumours from stage I patients tested positive for ALDH1. The relapse rate in ALDH1 + patients was 10 versus 51.2 % for ALDH1-. No differences in overall survival were observed between the groups; however, disease-free survival was 90 % for the ALDH1 + group versus 48.9 % for ALDH1- patients (p = 0.034). CONCLUSION: The patients in this study with ALDH1 + tumours had better outcomes than their counterparts with ALDH1- tumours. This finding suggests that not all CSCs are resistant to conventional cancer treatments. It may also imply that new methods of correctly identifying these cells are needed.
BACKGROUND:Aldehyde dehydrogenase isoform 1 (ALDH1) has been shown to be a marker of cancer stem cells (CSCs). These stem cells may be responsible for tumour perpetuation as well as local and distant invasion. Several studies have shown that CSCs are more chemoradiotherapy (CRT)-resistant and may be responsible for tumour recurrence. Other studies, in contrast, have found ALDH1 expression to be indicative of a better prognosis. METHODS: We retrospectively evaluated 84 patients diagnosed and treated for laryngeal cancer between 2006 and 2011. All patients underwent curative-intent radiotherapy or CRT at our institution. 57 of the 84 tumour samples contained sufficient material for ALDH1 assessment. RESULTS:ALDH1 expression was detected in 17.5 % (10/57) of the tissue samples. None of the tumours from stage I patients tested positive for ALDH1. The relapse rate in ALDH1 + patients was 10 versus 51.2 % for ALDH1-. No differences in overall survival were observed between the groups; however, disease-free survival was 90 % for the ALDH1 + group versus 48.9 % for ALDH1- patients (p = 0.034). CONCLUSION: The patients in this study with ALDH1 + tumours had better outcomes than their counterparts with ALDH1- tumours. This finding suggests that not all CSCs are resistant to conventional cancer treatments. It may also imply that new methods of correctly identifying these cells are needed.
Entities:
Keywords:
Aldehyde dehydrogenase; Cancer stem cells; Larynx carcinoma; Radiotherapy
Authors: Michael F Clarke; John E Dick; Peter B Dirks; Connie J Eaves; Catriona H M Jamieson; D Leanne Jones; Jane Visvader; Irving L Weissman; Geoffrey M Wahl Journal: Cancer Res Date: 2006-09-21 Impact factor: 12.701
Authors: Monique C de Jong; Jimmy Pramana; Jacqueline E van der Wal; Martin Lacko; Carine J Peutz-Kootstra; Jos M de Jong; Robert P Takes; Johannes H Kaanders; Bernard F van der Laan; Jasper Wachters; Jeroen C Jansen; Coen R Rasch; Marie-Louise F van Velthuysen; Reidar Grénman; Frank J Hoebers; Ed Schuuring; Michiel W van den Brekel; Adrian C Begg Journal: Clin Cancer Res Date: 2010-09-13 Impact factor: 12.531
Authors: Carmen Visus; Yangyang Wang; Antonio Lozano-Leon; Robert L Ferris; Susan Silver; Miroslaw J Szczepanski; Randall E Brand; Cristina R Ferrone; Theresa L Whiteside; Soldano Ferrone; Albert B DeLeo; Xinhui Wang Journal: Clin Cancer Res Date: 2011-08-19 Impact factor: 12.531
Authors: Nicholas Greco; Trevor Schott; Xiaodong Mu; Adam Rothenberg; Clifford Voigt; Richard L McGough; Mark Goodman; Johnny Huard; Kurt R Weiss Journal: J Cancer Ther Date: 2014-03-31
Authors: Xu Qian; Steffen Wagner; Chenming Ma; Jens P Klussmann; Michael Hummel; Andreas M Kaufmann; Andreas E Albers Journal: Oncol Rep Date: 2013-03-11 Impact factor: 3.906
Authors: Chao Chen; Yan Wei; Michael Hummel; Thomas K Hoffmann; Manfred Gross; Andreas M Kaufmann; Andreas E Albers Journal: PLoS One Date: 2011-01-27 Impact factor: 3.240
Authors: Yue Dong; Sebastian Ochsenreither; Chengxuan Cai; Andreas M Kaufmann; Andreas E Albers; Xu Qian Journal: PLoS One Date: 2017-11-07 Impact factor: 3.240